• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Tempest Reveals 2025 Financials And Business Update

    GLOBENEWSWIRE

    Tempest Therapeutics Announces Up To $6 Million Private Placement

    GLOBENEWSWIRE

    Tempest Partners on TPST-2003 Ahead of US Registrational Study

    GLOBENEWSWIRE

    Tempest Announces REDEEM-1 Interim Results for TPST-2003

    GLOBENEWSWIRE

    Tempest Outlines Plans for Newly Acquired Dual-Targeting CAR-T

    GLOBENEWSWIRE

    Tempest Finalizes Acquisition Of Dual-Targeting CAR-T Assets

    GLOBENEWSWIRE

    Tempest Sets Record Date For Warrant Dividend Distribution

    GLOBENEWSWIRE

    Tempest Initiates $8.35M Stock Offering With Warrant Placement

    GLOBENEWSWIRE

    Tempest Acquires Factor`s Dual-Car T Programs, Extends Runway

    GLOBENEWSWIRE

    Tempest Unveils Q3 2025 Financials & Business Update

    GLOBENEWSWIRE

    Tempest Reports Q1 2025 Financials and Business Update

    GLOBENEWSWIRE

    Tempest Unveils Amezalpat MOA Data at 2025 AACR Meeting

    GLOBENEWSWIRE

    Tempest lays off 80% of workforce to ride out cash crunch

    FIERCE BIOTECH

    Tempest, amid cash drought, hunts for liver cancer drug partner

    FIERCE BIOTECH

    Tempest Announces Amezalpat Poster at 2025 AACR Annual Meeting

    GLOBENEWSWIRE

    Tempest Reports Inducement Grant Under Nasdaq LR 5635(c)(4)

    GLOBENEWSWIRE

    Tempest to Attend Piper Sandler 36th Annual Healthcare Conference

    GLOBENEWSWIRE

    Tempest Reports Q3 2024 Financial Results & Business Update

    GLOBENEWSWIRE

    Tempest Extends Limited Duration Stockholder Rights Plan

    GLOBENEWSWIRE

    Tempest And Roche Agreement to Amezalpat For Hepatocellular Carcinoma

    GLOBENEWSWIRE

    Tempest Reports Inducement Grants Under Nasdaq Rule

    GLOBENEWSWIRE

    Tempest To Present At H.C. Wainwright Investment Conference

    GLOBENEWSWIRE

    Tempest Successfully Completes End-of-Phase 2 Meeting For Amezalpat

    GLOBENEWSWIRE

    Tempest soars on new data for TPST-1120 in first-line liver cancer

    YAHOO FINANCE

    Tempest Releases New Data Demonstrating Superiority of TPST-1120

    GLOBENEWSWIRE

    Tempest to Present Phase 1 Monotherapy & Combination Data at ASCO for TPST-1495

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.